Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityConvertible DebtCurrent AssetsCurrent Deferred RevenueCurrent LeasesLiabilities and Shareholders EquityLong-Term InvestmentsNon-Current AssetsNon-Current DebtOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesReceivables - NetRetained EarningsShareholder's EquityShort term DebtShort-term InvestmentsTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Cytokinetics (CYTK) Total Liabilities: 2010-2024

Historic Total Liabilities for Cytokinetics (CYTK) over the last 15 years, with Dec 2024 value amounting to $1.5 billion.

  • Cytokinetics' Total Liabilities rose 35.02% to $2.0 billion in Q3 2025 from the same period last year, while for Sep 2025 it was $2.0 billion, marking a year-over-year increase of 35.02%. This contributed to the annual value of $1.5 billion for FY2024, which is 26.96% up from last year.
  • Per Cytokinetics' latest filing, its Total Liabilities stood at $1.5 billion for FY2024, which was up 26.96% from $1.2 billion recorded in FY2023.
  • Over the past 5 years, Cytokinetics' Total Liabilities peaked at $1.5 billion during FY2024, and registered a low of $420.4 million during FY2020.
  • Its 3-year average for Total Liabilities is $1.3 billion, with a median of $1.2 billion in 2023.
  • Data for Cytokinetics' Total Liabilities shows a peak YoY soared of 87.91% (in 2022) over the last 5 years.
  • Cytokinetics' Total Liabilities (Yearly) stood at $420.4 million in 2020, then surged by 42.11% to $597.5 million in 2021, then surged by 87.91% to $1.1 billion in 2022, then climbed by 7.84% to $1.2 billion in 2023, then rose by 26.96% to $1.5 billion in 2024.